While these pathways are known to play critical roles in brain tumors, the levels, or ability, of ST6GAL1, ST6GAL2, or α2,6 sialylation to modulate BTIC signaling or maintenance to increase glioma growth has not been investigated. The gene discussed is ST6GAL1; the disease is central nervous system cancer.